ATXS
Astria Therapeutics, Inc. (ATXS) Economic Moat Analysis (2026)
Overall Score
Pricing Power
Gross profit margin is 100%, but the company still posts deeply negative operating and net margins, indicating no durable pricing power at the operating level.
Revenue per share remains extremely low relative to the share price, suggesting the market is pricing in future success rather than current monetization.
Cost Advantage
Operating expenses remain extremely heavy, with SG&A at 42.1% of revenue and R&D at 110.3% of revenue, which overwhelms gross profit.
Negative operating cash flow and free cash flow indicate the business does not yet have a cost structure advantage.
Switching Costs
There is no evidence of customer lock-in or recurring revenue durability in the current financials.
The very low asset turnover and weak cash generation suggest limited embedded customer dependence.
Network Effects
No financial evidence points to network effects or self-reinforcing scale benefits.
The company remains in a pre-moat profile with no visible user or transaction flywheel in the metrics.
Intangible Assets
R&D intensity is very high, but the financials do not show monetization of that spend through positive returns or margins.
No identifiable intangible asset base is visible in the balance sheet, and profitability remains deeply negative.
Scale Advantages
The company has a large cash balance and strong current ratio, but that does not translate into operating scale advantages.
Asset turnover is extremely low, indicating the business is not yet leveraging assets efficiently at scale.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Astria Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

